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Increasing evidence supports a crucial role for immuno-
logical and inflammatory responses in atherogenesis. The
development of atherosclerotic lesions involves interac-
tions between 4 major cell types: endothelial cells (ECs),
smooth muscle cells (SMCs), macrophages (MØ), and
lymphocytes (1, 2). The role of T cells in atherogenesis
remains unclear. However, because activated T cells accu-
mulate in atheroma — and by virtue of their early appear-
ance, persistence, and localization at sites of lesion growth
and rupture — they may orchestrate important aspects of
atherogenesis (3–7). Although atherosclerotic lesions con-
tain both CD8+ and CD4+ T cells, CD4+ memory
(CD45RO+) T cells predominate (8).
Previous studies have colocalized CD4+T lymphocytes
and IFN-g within human and mouse atherosclerotic
lesions (9), suggesting predominance of Th1 lympho-
cytes in atherogenesis (10). IFN-g plays a critical role in
modulating the cellular immune response by stimulat-
ing the production of proinflammatory cytokines, adhe-
sion molecules, and MHC class II expression by ECs,
SMCs, and MØ. Moreover, Gupta et al. have recently
demonstrated that apo E–knockout mice lacking the
IFN-g receptor developed fewer and smaller atheroscle-
rotic lesions than did control mice, suggesting that IFN-
g has proatherogenic properties (11).
Despite increasing evidence for involvement of T lym-
phocytes in atherogenesis, the mechanism of T-lympho-
cyte recruitment within the vascular atherosclerotic
lesions remains incompletely defined. Lymphocyte
recruitment into tissues is a multistep process involving
adhesion molecules and chemokines. Chemokines are
secreted basic proteins (8–10 kDa) subdivided into 4
families based on the relative position of their cysteine
residues (CC, CXC, C, CXC3) (12). CXC chemokines fur-
ther fall into 2 classes based on the presence or absence
of a NH2-terminal sequence Glutamic acid-Leucine-
Arginine (ELR). The ELR-containing CXC chemokines,
such as IL-8, chemoattract neutrophils (13), whereas the
non-ELR CXC chemokines chemoattract lymphocytes.
Among the non-ELR CXC chemokines, 3 of them — 
IP-10 (IFN-inducible protein 10), Mig (monokine
induced by IFN-g), and I-TAC (IFN-inducible T-cell a
chemoattractant) — are IFN-g inducible and potently
chemoattract activated T lymphocytes (14–18). All 3
chemokines signal through a common receptor, CXCR3,
expressed by memory (CD45RO+) T cells, preferentially
of the Th1 subset, and by natural killer cells, but not by
monocytes or neutrophils (15, 19–22). IP-10 has been
found in various clinical conditions in which activated
Th1 lymphocytes and IFN-gexpression were found, such
as psoriasis (23), tuberculoid leprosy (24), sarcoidosis
(25), viral meningitis (26), and pulmonary tuberculosis
(27). Mig was also found in psoriatic lesions by in situ
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Activated T lymphocytes accumulate early in atheroma formation and persist at sites of lesion growth and rup-
ture, suggesting that they may play an important role in the pathogenesis of atherosclerosis. Moreover, ath-
erosclerotic lesions contain the Th1-type cytokine IFN-g, a potentiator of atherosclerosis. The present study
demonstrates the differential expression of the 3 IFN-g–inducible CXC chemokines — IFN-inducible protein
10 (IP-10), monokine induced by IFN-g (Mig), and IFN-inducible T-cell achemoattractant (I-TAC) — by athero-
ma-associated cells, as well as the expression of their receptor, CXCR3, by all T lymphocytes within human ath-
erosclerotic lesions in situ. Atheroma-associated endothelial cells (ECs), smooth muscle cells (SMCs), and
macrophages (MØ) all expressed IP-10, whereas Mig and I-TAC were mainly expressed in ECs and MØ, as
detected by double immunofluorescence staining. ECs of microvessels within lesions also expressed abundant
I-TAC. In vitro experiments supported these results and showed that IL-1b, TNF-a, and CD40 ligand poten-
tiated IP-10 expression from IFN-g–stimulated ECs. In addition, nitric oxide (NO) treatment decreased IFN-g
induction of IP-10. Our findings suggest that the differential expression of IP-10, Mig, and I-TAC by athero-
ma-associated cells plays a role in the recruitment and retention of activated T lymphocytes observed within
vascular wall lesions during atherogenesis.
J. Clin. Invest. 104:1041–1050 (1999).hybridization (17). To date, I-TAC has not been correlat-
ed with any human diseases.
Chemokines such as IL-8, monocyte chemoattractant
protein-1 (MCP-1), MCP-4, and RANTES have been
shown to be expressed within atherosclerotic lesions in
situ and by atheroma-associated cells in vitro (28–35). In
addition, in recent in vivo studies, targeted disruption of
the genes for MCP-1, CCR2, and CXCR2 significantly
decreased atherosclerotic lesion formation and lipid dep-
osition when the disrupted gene was bred or transferred
into mouse strains prone to develop atherosclerotic-like
lesions (36, 37, 29). Furthermore, in these 3 in vivo stud-
ies, the attenuated development of vascular lesions cor-
related with decreased MØ accumulation in lesions,
demonstrating that chemokines play a critical role in
monocyte/MØ recruitment during atherogenesis.
It is likely that chemokines also play a critical role in
the recruitment and retention of activated T cells in ath-
erosclerosis. Because IFN-gappears to have a proathero-
genic effect, we have hypothesized that the IFN-
g–inducible chemokines IP-10, Mig, and I-TAC play an
important role in atherosclerosis. Moreover, we investi-
gated whether CD40 ligand (CD154), a molecule recent-
ly implicated in atherosclerosis (38, 39), and nitric oxide
(NO), which has an antiatherogenic effect (40, 41),
would regulate IP-10, Mig, and I-TAC expression.
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Figure 1
Expression of IP-10, Mig, and I-TAC in human atherosclerotic lesions in situ. Human carotid arteries sections were stained with specific antibodies
to IP-10, Mig, and I-TAC. High-power view (´100) of atherosclerotic lesions from different stages (Intimal thickening, Fatty streak, and Atheroma)
revealed the expression of the chemokines (red-brown reaction product). Adjacent sections of the same atherosclerotic carotid tissue stained for IP-
10 was stained with the rabbit preimmune IP-10 serum (´100). Normal human artery exhibited no expression of IP-10 (´100). The lumen of the
artery is at the upper left side of each photomicrograph. Analysis of 5–7 atheroma at each stage of lesion development from different donors, and
normal tissue from 4 different donors showed similar results.Methods
Reagents. Affinity-purified rabbit anti-human IP-10 poly-
clonal antibody was generated as described previously (42).
Rabbit anti-human Mig polyclonal antibody was obtained
from PeproTech Inc. (Rocky Hill, New Jersey, USA). Affin-
ity-purified rabbit anti-human I-TAC polyclonal antibody
was generated as described (18). Mouse anti-human
CXCR3 (1C6) mAb was a gift from LeukoSite(Cambridge,
Massachusetts, USA). The following human recombinant
cytokines were obtained from Endogen Inc. (Cambridge,
Massachusetts, USA): IFN-g, IL-1b, and
TNF-a. Human recombinant CD40 lig-
and (rCD40L) was a gift from P. Graber
(Ares Serono, Geneva, Switzerland) and
was generated as described previously
(43). The NO donors S-nitroso-N-
acetylpenicillamine (SNAP) and S-
nitrosoglutathione (GSNO) were pur-
chased from Sigma Chemical Co. (St.
Louis, Missouri, USA).
Cell isolation and culture. Human vas-
cular ECs were isolated from saphe-
nous veins by collagenase treatment
(1 mg/mL; Worthington Biochemical
Corp., Freehold, New Jersey, USA)
and were cultured in dishes coated
with fibronectin (1.5 mg/cm2; New
York Blood Center Reagents, New
York, New York, USA) as described
elsewhere (44). Cells were maintained
in M199 medium (BioWhittaker Inc.,
Walkersville, Maryland, USA) supple-
mented with 1% penicillin/strepto-
mycin (BioWhittaker Inc.), 5% FCS
(Atlanta Biologicals, Norcross, Geor-
gia, USA), 100 mg/mL heparin (Sigma
Chemical Co.), and 50 mg/mL EC
growth factor (ECGF; Pel-Freez Bio-
logicals, Rogers, Arkansas, USA).
Human vascular SMCs were isolated
from human saphenous veins and
carotid arteries by explant outgrowth
(38) and were cultured in DMEM
(BioWhittaker Inc.) supplemented
with 1% L-glutamine (BioWhittaker
Inc.), 1% penicillin/streptomycin, and
10% FCS. Both cell types were sub-
cultured after trypsinization (0.5%
trypsin [Worthington Biochemicals]
and 0.2% EDTA [EM Science, Gibb-
stown, New Jersey, USA]) in P100 cul-
ture dishes (Becton Dickinson and
Co., Franklin Lakes, New Jersey, USA)
and were used throughout passages
2–4. Culture media and FCS con-
tained less than 40 pg LPS/mL, as
determined by chromogenic Limulus
amoebocyte-lysote-assay analysis
(QLC-1000; BioWhittaker Inc.). ECs
and SMCs were characterized by
immunostaining with anti–von
Willebrand factor and anti–SMC a-
actin antibodies (DAKO Corp., Carpinteria, California,
USA), respectively. Both cell types were cultured 12
hours before the experiment in media lacking FCS; ECs
were cultured in M199 supplemented with 0.1% HSA
and SMCs cultured in insulin/transferrin (I/T) medi-
um with 0.1% BSA as described elsewhere (45).
Monocytes were isolated by adherence from PBMCs
after Ficoll-Hypaque gradient and were cultured in
RPMI-1640 medium (BioWhittaker Inc.) containing
10% FCS (Sigma Chemical Co.). Monocyte-derived MØ
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Figure 2
Colocalization of IP-10, Mig, and I-TAC with ECs, SMCs, and MØ in human atherosclerotic
lesions. High-power views (´400) of human carotid sections showed specific staining for IP-
10, Mig, and I-TAC (Texas red staining) within the atherosclerotic lesions. Cell types were char-
acterized by immunofluorescence staining with anti-CD31 mAb for ECs, anti–a-actin mAb for
SMCs, and anti-CD68 mAb for MØ (FITC; green staining). The lumen of the artery is at the top
of each photomicrograph. Analysis of atheroma from 3 different donors showed similar results.were serum starved 16 hours before experiments, and
stimulated with IFN-g in RPMI-1640 medium supple-
mented with 0.1% BSA.
Immunohistochemistry. Surgical specimens of human
carotid atheroma and normal aorta were obtained by pro-
tocols approved by the Human Investigation Review Com-
mittee at the Brigham and Women’s Hospital. Serial cryo-
stat sections (5 mm) were cut, air dried onto microscope
slides (Fisher Scientific Co., Pittsburgh, Pennsylvania,
USA), and fixed in acetone at –20°C for 5 minutes. Sec-
tions preincubated with PBS containing 0.3% hydrogen
peroxide were then incubated for 90 minutes with primary
or control antibody, diluted in PBS supplemented with 5%
appropriate serum. After washing 3 times in PBS, sections
were incubated with the respective biotinylated secondary
antibody (for 45 minutes; Vector Laboratories,
Burlingame, California, USA) followed by avidin-biotin-
peroxidase complex (VECTASTAIN ABC kit; Vector Lab-
oratories). Immunostaining was viewed using 3-amino-9-
ethyl carbazole (Vector Laboratories) according to the
recommendations provided by the supplier. Cell types
were characterized by double immunofluorescence stain-
ing using FITC-labeled cell-specific antibody (anti-muscle
actin mAb for SMCs (Enzo Diagnostics, New York, New
York), anti-CD31 mAb for ECs (DAKO Corp.), anti-CD68
mAb for MØ (DAKO Corp.), and anti-human CD3 for T
lymphocyte (DAKO Corp.).
Western blot analysis.Normal aortas and carotid athero-
sclerotic tissues were obtained from human patients
after surgery. Tissues were homogenized (Ultra-tarrax T
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Figure 3
Expression of I-TAC by ECs of microvessels
within human atherosclerotic lesions.
High-power views (´400) of human
carotid sections showed specific staining
for I-TAC (Texas red staining). Cell types
was characterized by immunofluorescence
staining of CD31 for ECs within the ather-
osclerotic lesions (FITC; green staining).
The lumen of the artery is at the top of
each photomicrograph. Analysis of
atheroma from 3 different donors showed
similar results.
Figure 4
Western blot analysis of vascular tissue
extracts. Samples (50 mg protein per lane)
from normal human aortas (Normal) and
human carotid atherosclerotic lesions
(Plaque) were analyzed for IP-10 and Mig
expression by Western blot. Analysis of 3
normal and 4 atherosclerotic tissues from
different donors are shown. Human
recombinant IP-10 (rIP-10) and Mig
(rMig) were used as controls. The posi-
tion of the molecular markers markers are
indicated (kDa).The Journal of Clinical Investigation | October 1999 | Volume 104 | Number 8 1045
Figure 6
Expression of CXCR3 on CD4+ T lymphocytes
within human atherosclerotic lesions. Sections
of human carotid arteries were stained with
anti-CXCR3 antibody. (a) Low-power (´100)
and (b) high-power (´400) views show CXCR3
expression (red-brown reaction product) in the
shoulder region of the plaque. Colocalization of
CD4+ lymphocytes (c) (FITC; green staining)
with CXCR3 (d) (Texas red staining) was per-
formed by immunofluorescence-double stain-
ing. The lumen of the artery is at the top of each
photomicrograph. Analysis of atheroma from 4
different donors showed similar results
Figure 5
Expression of the chemokine-receptor CXCR3 on T lymphocytes within human atherosclerotic lesions. Adjacent sections of human carotid arteries
at different stages (Intimal thickening, Fatty streak, and Atheroma) were stained with anti-CD3 or anti-CXCR3 antibody (arrows). Photomicrographs
(´100) reveal CD3 and CXCR3 expression (red-brown reaction product). The lumen of the artery is at the top of each photomicrograph. Analysis of
5–7 atheroma at each stage of lesion development from different donors showed similar results.25; IKA-Labortechnik, Wilmington, North Carolina,
USA)and lysed (0.3 g tissue/mL lysis buffer) as described
previously (46). Lysates were clarified (16,000 g for 15
minutes at 4°C), and protein concentration for each tis-
sue extract was determined using a bicinchoninic acid
(BCA) protein assay according to the instructions of the
supplier (Pierce Chemical Co., Rockford, Illinois, USA).
Fifty microgram of tissue lysates protein per lane and
supernatants (45 mL) of cultured ECs, SMCs, and mono-
cyte-derived MØ were separated by SDS-PAGE under
reducing conditions and blotted onto PVDF membranes
(Millipore Corp., Bedford, Massachusetts, USA) using a
semidry blotting apparatus (3.0 mA/cm2 for 30 minutes;
Bio-Rad Laboratories Inc., Hercules, California, USA).
Membranes were blocked in 5% defatted dry milk/
PBS/0.1% Tween-20 (PBST) and were then incubated with
the primary antibody (rabbit anti–IP-10 1:2,000; rabbit
anti-Mig 1:1,000; rabbit anti–I-TAC 1:500) for 1 hour. Blots
were washed 4 times PBST, and the secondary peroxidase-
conjugated antibody (Jackson ImmunoResearch Labora-
tories Inc., West Grove, Pennsylvania, USA) was added
(1:10,000) for another hour. Finally, membranes were
washed in PBST, and detection of the antigen was carried
out using the enhanced chemiluminescence detection
method according to the manufacturer’s recommenda-
tions (NEN Life Science Products Inc.,  Boston, Massa-
chusetts, USA), and subsequent exposure of the mem-
branes to x-ray film.
Northern blot analysis. Total RNA was extracted from
samples using Stat-60 (Tel-Test Inc., Friendswood, Texas,
USA). For Northern analysis, 20 mg total RNA was elec-
trophoresed on a 1.2% agarose-formaldehyde gel and
then capillary transferred to a GeneScreen membrane
(NEN Life Science Products Inc.). After overnight prehy-
bridization (50% formamide, 1% SDS, 4´ SSC, 4´ Den-
hardt’s solution, 0.8% glycine, and 0.17 mg/mL dena-
tured salmon sperm DNA) at 42°C, blots were
hybridized at 42°C in 50% formamide, 10% dextran, 1%
SDS, 5´ SSC, 1´ Denhardt’s solution, and 0.17 mg/mL
denatured salmon sperm DNA with 106 cpm/mL [a-
32P]dCTP–radiolabeled cDNA probe prepared by nick
translation. The following fragments were used as
probes: a 1-kb PstI fragment from hIP-10 cDNA, a 3-kb
NotI fragment from hMig cDNA (kindly provided by J.
Farber, National Institutes of Health, Bethesda, Mary-
land, USA), and a 300-bp BamHI/AvaI fragment from hI-
TAC cDNA. A GAPDH cDNA probe was used as a con-
trol for RNA loading. Signal quantitation was
determined using a phosphoimager (Molecular Imager
System; Bio-Rad Laboratories Inc.). Levels of chemokine
expression in any given sample were normalized to the
GAPDH signal for that sample. Because different expo-
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Figure 7
Expression of IP-10, Mig, and I-TAC by human ECs, SMCs, and mono-
cyte-derived MØ in vitro. (a) Northern blot and (b) Western analysis of
unstimulated (–) or IFN-g-stimulated (1,000 U/mL for 18 hours) (+) ECs,
SMCs, and monocyte-derived MØ was performed using 20 mg total RNA
per lane and 45 mL of unconcentrated cell supernatant per lane, respec-
tively. GAPDH was used as a control for RNA loading. Recombinant
chemokines (10 ng per lane) were used for controls in Western blots. For
Northern Blots, the IP-10 and I-TAC blots were exposed for 7 hours,
whereas the Mig blot was exposed for 70 hours. Similar results were
obtained in independent experiments with cells from 4 different donors.
Figure 8
Secretion of IP-10 protein by human ECs in response to cytokine stimula-
tion. Supernatants from human ECs unstimulated (–) or stimulated for 24
hours with IL-1b (10 ng/mL), TNF-a (50 ng/mL), IFN-g (100 U/mL), or
CD40L (5 mg/mL) were analyzed by ELISA for IP-10 levels. This figure is
representative of 3 separate experiments using ECs from different donors.
Error bars represent SD from triplicates (*P < 0.0001, **P < 0.005).sure times were used for each chemokine quanti-
tation and normalized to the same GAPDH expo-
sure, the ratio measurements can only be used to
compare levels of expression within any given
exposure of a blot and not between blots.
IP-10 ELISA assay. Release of IP-10 from cul-
tured human vascular ECs was measured using a
sandwich-type ELISA as described previously
(27). Antibody binding was detected by adding p-
nitrophenyl phosphate (Sigma Chemical Co.),
and absorbance was measured at 405 nm in a
Molecular Devices plate reader (Du Pont, Wilm-
ington, Delaware, USA). The amount of IP-10
detected was calculated from a standard curve
prepared with the recombinant protein. Samples
were assayed in triplicate.
Results
Human atheroma-associated cells express the chemokines
IP-10, Mig, and I-TAC. Immunohistochemical analy-
sis of human atherosclerotic plaques showed
expression of IP-10, Mig, and I-TAC within the
lesion (Figure 1). Analysis of atherosclerotic lesions
at different developmental stages from early inti-
mal thickening (n =5) through fatty streaks (n =5)
and fully developed atheroma lesions (n =7 )
revealed the expression of the 3 IFN-g–inducible
chemokines. Intimal thickening showed sparse but
reproducibly detectable expression of the
chemokines. In contrast, fatty streaks and well-
developed atheroma lesions consistently showed
strong immunoreactivity for all 3 chemokines,
most prominently at the luminal border and in the
shoulder region of the plaque, the margin between
the lesion and unaffected portion of the artery. No
immunoreactivity was observed in normal vessels (n =4)
or in atherosclerotic lesions examined with control pre-
immune serum as shown for IP-10 (Figure 1, lower pan-
els), confirming the specificity of the antibodies used in
these experiments. To characterize further the expression
of these chemokines within atherosclerotic lesions, we
performed double immunofluorescence staining (n =3)
using cell-specific antibodies. ECs, SMCs, and MØ high-
ly expressed IP-10 within human carotid atherosclerotic
plaques (Figure 2). In contrast, Mig was expressed most-
ly on ECs and MØ, and to a lesser extent on SMCs (Fig-
ure 2). The chemokine I-TAC was expressed only on ECs
and MØ (Figure 2). Furthermore, ECs within neovessel
formations in atherosclerotic plaques (n =3) expressed I-
TAC but little IP-10 or Mig (Figure 3).
To support these immunohistochemical results, West-
ern blot analyses were performed with the same chemokine
antibodies used for immunohistochemistry on tissue
extracts from human atherosclerotic (n = 6) and normal
vessels (n =4). The chemokines IP-10 and Mig were detect-
ed in 3 of 4 samples from atherosclerotic vessels and comi-
grated with the recombinant protein (Figure 4). Extracts of
unaffected arteries contained neither IP-10 nor Mig.
T lymphocytes within human atherosclerotic lesions express the
chemokine receptor CXCR3. In view of the finding that
atheroma-associated cells in situ expressed the 3 IFN-
g–inducible CXC chemokines — IP-10, Mig, and I-TAC —
we investigated the expression of their receptor, CXCR3,
in human atherosclerotic lesions. Serial sections of ath-
erosclerotic lesions adjacent to the ones used for exam-
ining the expression of IP-10, Mig and I-TAC (Figure 1)
were used to study the expression of CXCR3 (Figure 5).
Immunohistochemical analysis revealed the expression
of CXCR3+ cells within atherosclerotic lesions at all
stages of lesion development examined (intimal thick-
ening, fatty streak and atheroma; n = 5, 5, 7, respective-
ly). Adjacent sections of the same atherosclerotic tissue
stained for CD3 indicated that virtually all CD3+ cells
expressed CXCR3 (Figure 5). A comparison with the pat-
tern of expression seen for the chemokines (Figure 1),
revealed the colocalization of CXCR3+CD3+T cells with
the 3 CXCR3 ligands at all stages of atherogenesis.Dou-
ble immunofluorescence staining (n =4) with CD4 anti-
body indicated that virtually all CD4+ T cells expressed
CXCR3+(Figure 6). As demonstrated in previous studies
(8), we also found that the vast majority of CD3+ cells
were CD4+ lymphocytes (data not shown).
Atheroma-associated cells in vitro express the chemokines IP-
10, Mig and I-TAC. To characterize further IP-10, Mig and
I-TAC expression by atheroma-associated cells, we per-
formed in vitro experiments using human vascular ECs,
SMCs and human monocyte-derived MØ. Quiescent
cells lacked detectable IP-10, Mig, and I-TAC mRNA or
protein expression (Figure 7). IFN-g (1,000 U/mL for 18
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Figure 9
NO regulation of IFN-g–induced IP-10, Mig, and I-TAC from human vascular
ECs. (a) Northern blot analysis of unstimulated (None) or IFN-g–stimulated
(100 U/mL for 24 hours) ECs pretreated with various concentration of the NO
donor SNAP. GAPDH was used as a control for RNA loading. The IP-10, Mig,
and I-TAC blots were exposed for 6 hours, 24 hours, and 20 hours, respectively.
(b) Quantification of Northern blots expressed as the ratio of
chemokine/GAPDH signal for each sample using a phosphoimager to normal-
ize for differences in RNA loading between samples on a given blot. Because of
differences in exposure times used for the quantification, comparisons of
chemokine expression can only be made within a given blot. Similar results were
obtained in independent experiments with cells from 4 different donors.hours) induced IP-10 mRNA accumulation in ECs and
MØ and, to a lesser extent, in SMCs. Mig mRNA was
detected in ECs and to a lesser extent in MØ and SMCs
after IFN-g stimulation. In contrast, I-TAC mRNA was
highly expressed by ECs and was not detected in SMCs
and MØ. IP-10, Mig and I-TAC mRNA induction by IFN-
g in ECs depended on the concentration and time of
stimulation; mRNA for all 3 chemokines accumulated
after stimulation with as little as 10 U/mL of IFN-g and
occurred as early as 2 hours after stimulation (data not
shown). Viewing of Mig mRNA expression in SMCs
required a longer exposure of the blots shown in Figure
7a. Western blot analysis for IP-10, Mig, and I-TAC
extended Northern blot results to detection of all 3 pro-
teins after IFN-g stimulation in ECs (Figure 7b). The
absence of I-TAC and Mig detection in SMCs and mono-
cyte-derived MØ supernatants is likely due to lower con-
centrations compared with ECs supernatants. The con-
trol bands were loaded with 10 ng recombinant protein,
enabling quantitative comparisons between levels of
chemokine expression.
Stimulation of human ECs and SMCs with other
cytokines implicated in atherosclerosis, such as IL-1b(10
ng/mL), TNF-a(50 ng/mL), and CD40L (5 mg/mL) each
by itself, had no effect on IP-10 mRNA (data not shown)
or protein expression (Figure 8). However, IL-1b, TNF-a,
and CD40L synergized with IFN-gin inducing the secre-
tion of IP-10 protein in ECs as measured by an IP-
10–specific sandwich ELISA (27) (compared with IFN-g
alone; 4.2-fold for IL-1b/IFN-g;3.7-fold for TNF-a/IFN-
g; and 2.0-fold for CD40L/IFN-g).
NO decreases IP-10, Mig, and I-TAC mRNA and protein
expression by human vascular ECs. Incubation of human
vascular ECs with the NO donor SNAP before IFN-g
stimulation caused a concentration-dependent
decrease in IP-10, Mig, and I-TAC mRNA induction
(Figure 8a). This effect was more pronounced for IP-10
and Mig than for I-TAC mRNA expression. The NO
donor GSNO produced similar results (data not
shown). Phosphoimager analysis showed that maximal
effect (4.9-, 5.2-, and 1.5-fold decrease for IP-10, Mig,
and I-TAC, respectively) was obtained with 1 mM SNAP
(Figure 8b). The concentrations of NO donors
described in these experiments were similar to those
previously reported to act on vascular cells (47, 48), and
the lowest concentration used (50 mM) still affected
chemokine expression. Western blot analysis of super-
natants from IFN-g–stimulated ECs showed a similar
decrease for IP-10 and Mig protein secretion after NO
treatment (data not shown).
Discussion
Atherosclerotic lesions at all stages of development from
fatty streaks to complicated plaques contain cells and
molecules characteristic of immune-mediated processes
(2). Macrophages and lymphocytes are the most numer-
ous inflammatory cells found in atherosclerotic lesions.
These cells elaborate growth factors and cytokines that
mediate intimal hyperplasia and may therefore promote
atherogenesis. Activated T lymphocytes accumulate early
in atheroma formation and persist at sites of lesion
growth and rupture, suggesting that they play an impor-
tant role in atherogenesis (49–51). Moreover, the Th1-
type cytokine IFN-g is expressed in atherosclerotic
lesions (10) and can promote atherosclerosis in vivo (11).
In addition, experiments using mutant mice deficient in
both apo E and RAG-1 (T- and B-cell deficient) suggest a
functional role for lymphocytes in atherogenesis by
revealing a 40% reduction in atherosclerotic lesions com-
pared with immunocompetent apo E–deficient mice
(52). Although the mechanism of monocyte recruitment
within mouse atherosclerotic lesions involves the CC
chemokine MCP-1 and its receptor CCR2 (36, 37), hom-
ing and accumulation of activated T lymphocytes in ath-
erosclerotic lesions remain poorly understood. The pres-
ent study investigated the expression of the 3
IFN-g-inducible CXC chemokines, IP-10, Mig, and I-
TAC, which specifically chemoattract activated T cells,
through the receptor CXCR3.
Our data show expression of immunoreactive IP-10,
Mig, and I-TAC within human atherosclerotic plaques
but not within the normal vessel wall. We are unaware of
previous reports of I-TAC expression related to a human
disease or of the expression of the 3 IFN-g–inducible
CXC chemokines and their receptor CXCR3 simultane-
ously in the same diseased tissue. Using double
immunofluorescence, we found that IP-10 was expressed
by ECs, SMCs, and MØ, whereas Mig and I-TAC were
predominantly expressed by ECs and MØ, consistent
with an hypothesis that these 3 chemokines have nonre-
dundant roles in T-cell trafficking in atherosclerotic
lesions. In fact, I-TAC is a more efficacious chemoat-
tractant than IP-10 or Mig for CXCR3+ T cells in vitro,
and we have recently determined that among its ligands,
only I-TAC can effectively downregulate CXCR3 expres-
sion on activated T cells (A. Sauty et al., unpublished
observations). I-TAC may serve to capture and arrest acti-
vated T cells on the endothelium. The high expression of
I-TAC, but not IP-10 or Mig, by ECs in neovessels within
atherosclerotic plaques supports this hypothesis, as
inflammatory cell recruitment into established athero-
ma may involve these neovessels. The ability of I-TAC to
reduce cell surface CXCR3 expression may then facilitate
T-cell diapedesis at this site. Moreover, the abundant
expression of IP-10 by all 3 atheroma-associated cells, in
particular SMCs, and the inability of IP-10 to limit
CXCR3 expression, may facilitate T-cell retention with-
in the lesion. In addition, the finding that all lesional T
lymphocytes express CXCR3 agrees with the concept
that these 3 IFN-g–inducible chemokines play a role in
the recruitment and retention of activated T lympho-
cytes within vascular wall lesions during the process of
atherosclerosis.
Concordant with our in situ observations, we found
strong expression of IP-10 mRNA and protein by IFN-
g–activated ECs, SMCs, and MØ in vitro. Lower levels of
Mig mRNA were seen in activated ECs and MØ, but Mig
protein was only detected in ECs supernatants. I-TAC
mRNA andprotein were detected only in IFN-g–activated
ECs. The discrepancy between I-TAC expression by
macrophages in situ and by IFN-g–activated peripheral
blood monocyte–derived MØ in vitro likely reflects the
activation of lesional macrophages by other stimuli in
addition to IFN-g. This study also examined the regula-
1048 The Journal of Clinical Investigation | October 1999 | Volume 104 | Number 8tion of these chemokines in atheroma-associated cells by
NO, another agent implicated in the pathogenesis of ath-
erosclerosis. Normal vascular ECs secrete NO in response
to shear stress, whereas ECs overlying atherosclerotic
plaques produce less NO (41). In addition to its vascular
relaxing effects, NO plays important immunoregulatory
functions, such as inhibiting nuclear factor-kB (NF-kB)
activation. We found that exogenous NO limits IP-10,
Mig, and, to a lesser extent, I-TAC, mRNA accumulation
induced by IFN-gin ECs. Along these lines, exogenous NO
inhibits (by 25%) IL-1–induced IL-8 secretion from ECs
(53), and inhibition of basal NO production upregulates
EC MCP-1 mRNA and protein expression (48). These
results suggest that diminished secretion of NO by ECs
leads to an increase in cytokine-induced chemokine
expression by these cells and, therefore, to a greater stim-
ulus for leukocyte recruitment into atherosclerotic lesions.
In addition, we observed that the CD40 pathway, recent-
ly implicated in atherogenesis, potentiated the IFN-
g–induced secretion of IP-10 from ECs. CD40 ligation
induces MIP-1a, MIP-1b, RANTES, and MCP-1 in
macrophages (54) and, thus, may participate in atheroge-
nesis through the release of multiple chemokines.
Chemokines may not only influence leukocyte recruit-
ment within atherosclerotic lesions, but they may also
regulate a number of vascular cell and leukocyte func-
tions related to the acute and chronic manifestations of
atherosclerosis. In particular, IP-10 mRNA was induced
in the rat carotid artery after balloon angioplasty and
was shown to be a mitogenic and chemotactic factor for
vascular SMCs (55), suggesting that IP-10 might be
involved in vascular remodeling during atherosclerosis.
In addition, IP-10 inhibits neovascularization and
wound healing in vivo (56), activities that may con-
tribute to the necrosis associated with atherosclerotic
lesions. Furthermore, IP-10 augments IFN-gproduction
from Th1 cells (57) and thus may help establish an
autocrine loop that serves to drive the inflammatory
response within the diseased vessel. Thus, in addition to
recruiting activated T cells, these IFN-g–inducible
chemokines may play a role in the pathogenesis of ath-
erosclerosis by regulating SMC and EC function.
In conclusion, we have demonstrated that atheroma-
associated cells in situ differentially express the 3 IFN-
g–inducible CXC chemokines IP-10, Mig, and I-TAC, and
that all CD4+ T lymphocytes within the same lesions
express their receptor CXCR3. The coexpression of these
chemokines and their receptor within atherosclerotic
lesions suggests their involvement in the regulation of
lymphocyte recruitment into atherosclerotic lesions, and
that neutralization of this pathway in vivo may modu-
late immune cell migration within vascular wall during
atherogenesis.
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